MacroGenics, Inc. (MGNX)
3.75
-0.05
(-1.32%)
USD |
NASDAQ |
Sep 25, 16:00
3.75
0.00 (0.00%)
After-Hours: 19:59
MacroGenics Research and Development Expense (Annual) : 140.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 140.00M |
| December 31, 2024 | 169.65M |
| December 31, 2023 | 156.94M |
| December 31, 2022 | 195.16M |
| December 31, 2021 | 203.32M |
| December 31, 2020 | 181.24M |
| December 31, 2019 | 183.01M |
| December 31, 2018 | 190.83M |
| Date | Value |
|---|---|
| December 31, 2017 | 147.23M |
| December 31, 2016 | 122.09M |
| December 31, 2015 | 98.27M |
| December 31, 2014 | 70.19M |
| December 31, 2013 | 45.39M |
| December 31, 2012 | 44.47M |
| December 31, 2011 | 39.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences, Inc. | 5.688B |
| Xencor, Inc. | 239.43M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |